Expressions of ETS2 in colorectal cancer tissues and its clinical significance

doi:10.3877/cma.j.issn.2095-3224.2019.06.004

Abstract

Abstract:

Objective

To investigate the expressions of ETS2 (E-twenty six 2) in colorectal cancer tissues, analyze the relationships between clinic-pathological parameters and ETS2 expression, and evaluate its clinical prognostic value.

Methods

We collected fresh colorectal cancer, paracancerous and the corresponding normal tissues, and specimens of paraffin of colorectal cancer and adjacent to carcinoma. Real-time fluorescent quantitative PCR and immunohistochemistry were used to detect ETS2 mRNA expression and protein expression respectively.

Results

Our results showed that the expression of ETS2 mRNA in colorectal cancer tissues was significantly higher than that in adjacent and normal tissues (P<0.001), while there was no significant difference between adjacent and normal tissues (P>0.05). Immuno-histochemical results showed that ETS2 was expressed in 52.07% (63/121) colorectal cancer tissues, but only in 13.04% (6/46) para-cancerous tissues, showing a significant difference (P<0.05). ETS2 expression was closely associated with tumor differentiation, invasion depth, lymph node metastasis, and MMR status (all P<0.05). ETS2 expression was associated with postoperative progression-free survival in patients with colorectal cancer (P<0.001). Multivariate regression analysis using Cox model showed that ETS2 expression (HR: 0.461, 95% CI: 0.271~0.683, P=0.003) and infiltration depth (HR: 0.352, 95% CI: 0.113~0.769, P=0.015) were independent prognostic factors for postoperative progressive-free survival of colorectal cancer patients.

Conclusion

Compared with para-cancerous tissues, ETS2 was overexpressed in transcriptional and translational levels of colorectal cancer. Moreover, ETS2 was a potential marker for predicting postoperative progression-free survival in patients.

Key words: Colorectal neoplasms, Prognosis, ETS2, Infiltration depth, Marker

Jun Wang, Yu Huang, Qiang Sun, Shuxun Wei, Xujun Zhu, Changming Wang, Xinxing Li, Jian Xu. Expressions of ETS2 in colorectal cancer tissues and its clinical significance[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2019, 08(06): 560-565.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2019.06.004

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2019/V08/I06/560

Figures/Tables 5

References 20

[1]	Han S, Gao J, Zhou Q, et al. Role of intestinal flora in colorectal cancer from the metabolite perspective: a systematic review [J]. Cancer Management and Research, 2018, 10: 199-206.
[2]	de Klerk CM, Gupta S, Dekker E, et al. Expert Working Group ′Coalition to reduce inequities in colorectal cancer screening′ of the World Endoscopy O. Socioeconomic and ethnic inequities within organised colorectal cancer screening programmes worldwide [J]. Gut, 2018, 67(4): 679-687.
[3]	Kayser K, Acquati C, Reese JB, et al. A systematic review of dyadic studies examining relationship quality in couples facing colorectal cancer together [J]. Psycho-oncology, 2018, 27(1): 13-21.
[4]	Fry EA, Inoue K. Aberrant expression of ETS1 and ETS2 proteins in cancer [J].Cancer reports and reviews, 2018, 2(3): 10.
[5]	Zhang G, Zhang L, Yang X, et al. High ETS2 expression predicts poor prognosis in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation [J]. Annals of hematology, 2019, 98(2): 519-525.
[6]	Wallace JA, Li F, Balakrishnan S, et al. Ets2 in tumor fibroblasts promotes angiogenesis in breast cancer [J]. PloS One, 2013, 8(8): e71533.
[7]	Torres A, Alshalalfa M, Davicioni E, et al. ETS2 is a prostate basal cell marker and is highly expressed in prostate cancers aberrantly expressing p63 [J]. The Prostate, 2018, 78(12): 896-904.
[8]	Fry EA, Mallakin A, Inoue K. Translocations involving ETS family proteins in human cancer [J]. Integrative cancer science and therapeutics, 2018, 5(4): 4-12.
[9]	Zhang GW, Tian X, Li Y, et al. Down-regulation of ETS2 inhibits the invasion and metastasis of renal cell carcinoma cells by inducing EMT via the PI3K/Akt signaling pathway [J]. Biomedicine & pharmacotherapy, 2018, 104: 119-126.
[10]	Liu DD, Kang Y. Ets2 anchors the prometastatic function of mutant p53 in osteosarcoma [J]. Genes & development, 2017, 31(18): 1823-1824.
[11]	Peraki I, Palis J, Mavrothalassitis G. The Ets2 Repressor Factor (Erf) Is Required for Effective Primitive and Definitive Hematopoiesis [J]. Molecular and cellular biology, 2017, 37(19): e00183-17.
[12]	Ma S, Fang Z, Luo W, et al. The C-ETS2-TFEB axis promotes neuron survival under oxidative stress by regulating lysosome activity [J]. Oxidative medicine and Cellular Longevity, 2016, 2016: 4693703.
[13]	Liu X, Zhang C, Zhang Z, et al. E26 transformation-specific transcription factor ETS2 as an oncogene promotes the progression of hypopharyngeal cancer [J]. Cancer biotherapy & radiopharmaceuticals, 2017, 32(9): 327-334.
[14]	Baker K, Foulkes WD, Jass JR. MSI-H colorectal cancers preferentially retain and expand intraepithelial lymphocytes rather than peripherally derived CD8+ T cells[J]. Cancer Immunology, Immunotherapy: CII, 2009, 58(1): 135-144.
[15]	Lawes DA, Pearson T, Sengupta S, et al. Is MSI-H of value in predicting the development of metachronous colorectal cancer? [J]. European Journal of Cancer, 2006, 42(4): 473-476.
[16]	Lee JJ, Chu E. Recent advances in the clinical development of immune checkpoint blockade therapy for mismatch repair proficient (pMMR)/non-MSI-H metastatic colorectal cancer [J]. Clinical Colorectal Cancer, 2018, 17(4): 258-273.
[17]	Gatalica Z, Vranic S, Xiu J, et al. High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicine [J]. Familial cancer, 2016, 15(3): 405-412.
[18]	Sclafani F. PD-1 inhibition in metastatic dMMR/MSI-H colorectal cancer [J]. The Lancet Oncology, 2017, 18(9): 1141-1142.
[19]	Diaz LA. The promise of liquid biopsy in colorectal cancer [J]. Clinical Advances in Hematology & Oncology: H&O, 2014, 12(10): 688-689.
[20]	Ray K. Colorectal cancer: Liquid biopsy enables real-time monitoring of molecular alterations in CRC [J]. Nature reviews Gastroenterology & hepatology, 2015, 12(7): 372.

参数		例数	ETS2表达		检验值	P值
参数		例数	低表达	高表达	检验值	P值
性别		?	?	?	0.007	0.935
?	女	34	17	17	?	?
?	男	87	41	46	?	?
年龄（岁）		?	?	?	0.012	0.911
?	≤60	38	19	19	?	?
?	>60	83	39	44	?	?
肿瘤直径（cm）		?	?	?	1.943	0.163
?	≤3	99	44	55	?	?
?	>3	22	14	8	?	?
肿瘤位置		?	?	?	0.871	0.351
?	结肠	73	38	35	?	?
?	直肠	48	20	28	?	?
分化程度		?	?	?	19.577	<0.001
?	中/高分化	38	30	8	?	?
?	低/未分化	83	28	55	?	?
浸润深度		?	?	?	22.036	<0.001
?	T1	44	34	10	?	?
?	T2-T4	77	24	53	?	?
淋巴结转移		?	?	?	9.593	0.002
?	N0	69	42	27	?	?
?	N1-N2	52	16	36	?	?
MMR状态		?	?	?	4.811	0.028
?	MSS	80	42	38	?	?
?	MSI	41	16	35	?	?
进展*		?	?	?	7.042	0.008
?	有	55	25	30	?	?
?	无	34	26	8	?	?

参数		例数	ETS2表达		检验值	P值
参数		例数	低表达	高表达	检验值	P值
性别		?	?	?	0.007	0.935
?	女	34	17	17	?	?
?	男	87	41	46	?	?
年龄（岁）		?	?	?	0.012	0.911
?	≤60	38	19	19	?	?
?	>60	83	39	44	?	?
肿瘤直径（cm）		?	?	?	1.943	0.163
?	≤3	99	44	55	?	?
?	>3	22	14	8	?	?
肿瘤位置		?	?	?	0.871	0.351
?	结肠	73	38	35	?	?
?	直肠	48	20	28	?	?
分化程度		?	?	?	19.577	<0.001
?	中/高分化	38	30	8	?	?
?	低/未分化	83	28	55	?	?
浸润深度		?	?	?	22.036	<0.001
?	T1	44	34	10	?	?
?	T2-T4	77	24	53	?	?
淋巴结转移		?	?	?	9.593	0.002
?	N0	69	42	27	?	?
?	N1-N2	52	16	36	?	?
MMR状态		?	?	?	4.811	0.028
?	MSS	80	42	38	?	?
?	MSI	41	16	35	?	?
进展*		?	?	?	7.042	0.008
?	有	55	25	30	?	?
?	无	34	26	8	?	?

预后因素	单因素分析			多因素分析
预后因素	RR	95%CI	P值	RR	95%CI	P值^#
性别	1.013	0.678~1.644	0.732	?	?	?
年龄（岁）	1.018	0.772~1.809	0.453	?	?	?
肿瘤直径（cm）	0.943	0.525~1.372	0.563	?	?	?
肿瘤位置	1.291	0.821~2.692	0.702	?	?	?
分化程度	0.094	0.175~0.457	0.001	0.816	0.124~2.706	0.114
浸润深度	0.303	0.156~0.489	0.002	0.352	0.113~0.769	0.015
淋巴结转移是否	0.413	0.263~0.509	0.011	0.795	0.271~2.281	0.670
病理分期	0.203	0.052~0.317	0.001	0.422	0.313~0.569	0.005
MMR状态	0.403	0.356~0.889	0.037	0.852	0.683~1.678	0.502
ETS2表达	0.251	0.161~0.411	0.000	0.461	0.271~0.683	0.003

预后因素	单因素分析			多因素分析
预后因素	RR	95%CI	P值	RR	95%CI	P值^#
性别	1.013	0.678~1.644	0.732	?	?	?
年龄（岁）	1.018	0.772~1.809	0.453	?	?	?
肿瘤直径（cm）	0.943	0.525~1.372	0.563	?	?	?
肿瘤位置	1.291	0.821~2.692	0.702	?	?	?
分化程度	0.094	0.175~0.457	0.001	0.816	0.124~2.706	0.114
浸润深度	0.303	0.156~0.489	0.002	0.352	0.113~0.769	0.015
淋巴结转移是否	0.413	0.263~0.509	0.011	0.795	0.271~2.281	0.670
病理分期	0.203	0.052~0.317	0.001	0.422	0.313~0.569	0.005
MMR状态	0.403	0.356~0.889	0.037	0.852	0.683~1.678	0.502
ETS2表达	0.251	0.161~0.411	0.000	0.461	0.271~0.683	0.003

Please choose a citation manager

Content to export